Forest Expects Lexapro Scripts To Grow 2%-3% Through Lilly Cymbalta Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Lexapro's safety profile will be a distinguishing feature as Lilly launches its SNRI, Forest says. In its first full year of sales, Lexapro tops the $1 bil. mark.
You may also be interested in...
Forest Expects Multiple Celexa Generics To Enter Market In January
Company sees "no impediments" to ANDA approvals for antidepressant, beyond demands on FDA resources to review multiple applications simultaneously. Forest believes the agency will try to approve all generics simultaneously, making it difficult to complete the reviews before the end of the year.
Forest Expects Multiple Celexa Generics To Enter Market In January
Company sees "no impediments" to ANDA approvals for antidepressant, beyond demands on FDA resources to review multiple applications simultaneously. Forest believes the agency will try to approve all generics simultaneously, making it difficult to complete the reviews before the end of the year.
Antidepressant Warnings On Pediatric Suicide Need Immediate Strengthening, Cmte. Says
A joint FDA advisory committee says suicide risk warnings should be communicated to physicians and consumers while the agency re-analyzes pediatric data from antidepressant manufacturers.